JO3489B1 - مركبات تراي أزولوبيريميدين واستخداماتها - Google Patents

مركبات تراي أزولوبيريميدين واستخداماتها

Info

Publication number
JO3489B1
JO3489B1 JOP/2015/0331A JOP20150331A JO3489B1 JO 3489 B1 JO3489 B1 JO 3489B1 JO P20150331 A JOP20150331 A JO P20150331A JO 3489 B1 JO3489 B1 JO 3489B1
Authority
JO
Jordan
Prior art keywords
triazolopyrimidines
shireen
image002
appdata
prc2
Prior art date
Application number
JOP/2015/0331A
Other languages
English (en)
Inventor
Sendzik Martin
Mi Yuan
Huang Ying
Justin Gu Xiang-Ju
Man Chan Ho
Yu Zhengtian
Yue Ji (Jeff) Zhang
Zhao Kehao
Sun Yongfeng
Zhang Hailong
Li Ling
Zhang Man
Zhang Qiong
Qi Wei
Wang Long
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of JO3489B1 publication Critical patent/JO3489B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

يتعلق الاختراع الحالي بتوفير مركب من الصيغة (I)، أو ملح مقبول صيدلانيا منه، والذي اتضح أنه مفيد في علاج مرض أو اضطراب ناتج عن PRC2: حيث R1، وR2، وR3، وR4، وR5، وn هي كما هي محددة هن <img src="file:///C:/Users/shireen.s/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />
JOP/2015/0331A 2014-12-23 2015-12-22 مركبات تراي أزولوبيريميدين واستخداماتها JO3489B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2014094644 2014-12-23
CN2015095320 2015-11-23

Publications (1)

Publication Number Publication Date
JO3489B1 true JO3489B1 (ar) 2020-07-05

Family

ID=55071101

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2015/0331A JO3489B1 (ar) 2014-12-23 2015-12-22 مركبات تراي أزولوبيريميدين واستخداماتها

Country Status (40)

Country Link
US (5) US9580437B2 (ar)
EP (1) EP3237418B1 (ar)
JP (1) JP6736559B2 (ar)
KR (1) KR102534028B1 (ar)
CN (1) CN107108637B (ar)
AU (1) AU2015370524B2 (ar)
BR (1) BR112017010354B8 (ar)
CA (1) CA2969090C (ar)
CL (1) CL2017001572A1 (ar)
CO (1) CO2017005992A2 (ar)
CR (1) CR20170285A (ar)
CY (1) CY1121901T1 (ar)
DK (1) DK3237418T3 (ar)
DO (1) DOP2017000149A (ar)
EA (1) EA032416B1 (ar)
EC (1) ECSP17047153A (ar)
ES (1) ES2722048T3 (ar)
GT (1) GT201700146A (ar)
HR (1) HRP20190805T1 (ar)
HU (1) HUE043060T2 (ar)
IL (1) IL252135B (ar)
JO (1) JO3489B1 (ar)
LT (1) LT3237418T (ar)
ME (1) ME03385B (ar)
MX (1) MX375970B (ar)
MY (1) MY186837A (ar)
NZ (1) NZ731664A (ar)
PE (1) PE20171307A1 (ar)
PH (1) PH12017501016B1 (ar)
PL (1) PL3237418T3 (ar)
PT (1) PT3237418T (ar)
RS (1) RS58679B1 (ar)
SG (1) SG11201703880VA (ar)
SI (1) SI3237418T1 (ar)
SV (1) SV2017005472A (ar)
TN (1) TN2017000204A1 (ar)
TW (1) TWI694076B (ar)
UA (1) UA120945C2 (ar)
UY (1) UY36462A (ar)
WO (1) WO2016103155A1 (ar)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108637B (zh) * 2014-12-23 2019-10-29 诺华股份有限公司 三唑并嘧啶化合物及其用途
US11786533B2 (en) 2016-06-01 2023-10-17 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
IL263429B (en) 2016-06-20 2022-08-01 Novartis Ag Crystalline forms of triazolopyrimidine compound
US10676479B2 (en) 2016-06-20 2020-06-09 Novartis Ag Imidazolepyridine compounds and uses thereof
WO2017221092A1 (en) * 2016-06-20 2017-12-28 Novartis Ag Triazolopyridine compounds and uses thereof
PH12019500056B1 (en) 2016-07-12 2024-01-31 Revolution Medicines Inc 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
CN106831601A (zh) * 2017-01-13 2017-06-13 河北博伦特药业有限公司 一种2‑氨基甲基嘧啶盐酸盐及其衍生物的合成方法
SG11201906412SA (en) 2017-01-23 2019-08-27 Revolution Medicines Inc Pyridine compounds as allosteric shp2 inhibitors
BR112019015075A2 (pt) 2017-01-23 2020-03-10 Revolution Medicines, Inc. Compostos bicíclicos como inibidores de shp2 alostéricos
WO2018170290A1 (en) * 2017-03-15 2018-09-20 Fulcrum Therapeutics, Inc. Compositions and methods for increasing fmr1 expression
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
WO2018166493A1 (zh) * 2017-03-16 2018-09-20 江苏恒瑞医药股份有限公司 杂芳基并[4，3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
WO2018223030A1 (en) 2017-06-02 2018-12-06 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
WO2019062435A1 (zh) * 2017-09-28 2019-04-04 中国科学院上海药物研究所 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
CN109575013A (zh) * 2017-09-28 2019-04-05 中国科学院上海药物研究所 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
SG11202002941WA (en) 2017-10-12 2020-04-29 Revolution Medicines Inc Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
CN109867645B (zh) * 2017-12-05 2021-09-14 中国医学科学院药物研究所 一种2,2-二氟-2,3-二氢取代苯并呋喃类化合物的合成方法
CA3084058A1 (en) * 2017-12-15 2019-06-20 Revolution Medicines, Inc. Polycyclic compounds as allosteric shp2 inhibitors
CN109942556A (zh) * 2017-12-21 2019-06-28 上海青煜医药科技有限公司 嘧啶酮化合物及其应用
WO2019145176A1 (en) * 2018-01-23 2019-08-01 Basf Se Halogenation of pyridine derivatives
NZ766447A (en) 2018-01-31 2021-12-24 Mirati Therapeutics Inc Prc2 inhibitors
CN110156787B (zh) * 2018-02-13 2021-11-02 中国科学院上海药物研究所 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途
CN110563722A (zh) * 2018-06-06 2019-12-13 上海青煜医药科技有限公司 吡啶或哒嗪并环化合物及其应用
CN110734436A (zh) * 2018-07-19 2020-01-31 上海青煜医药科技有限公司 嘧啶或吡嗪并环化合物及其应用
EP3889153A4 (en) * 2018-11-30 2022-09-07 Tuojie Biotech (Shanghai) Co., Ltd. PYRIMIDINE AND FIVE-MEMBERED HETEROCYCLIC NITROGEN DERIVATIVE, METHOD OF MANUFACTURE THEREOF AND MEDICAL USES THEREOF
CN111518100A (zh) * 2019-02-02 2020-08-11 上海青煜医药科技有限公司 环丙烯并苯并呋喃取代的氮杂芳基化合物及其应用
CA3133751A1 (en) 2019-03-15 2020-09-24 Fulcrum Therapeutics, Inc. Macrocyclic azolopyridine derivatives as eed and prc2 modulators
EP3950064A4 (en) * 2019-04-03 2023-01-04 Tera Stone Co., Ltd THYMINE NUCLEOBASE BASED TRIAZOLOPYRIMIDINES AND PROCESS FOR THEIR PRODUCTION
JP7624404B2 (ja) * 2019-04-22 2025-01-30 ミラティ セラピューティクス，インク． Ｐｒｃ２阻害剤としてのナフチリジン誘導体
WO2020231723A1 (en) 2019-05-13 2020-11-19 Ecolab Usa Inc. 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor
JP2022535267A (ja) * 2019-06-05 2022-08-05 アセネックス インコーポレイテッド 乾癬を治療および／または予防する方法
AU2020288563A1 (en) * 2019-06-05 2022-01-06 Mirati Therapeutics, Inc. Imidazo(1,2-c)pyrimidine derivatives as PRC2 inhibitors for treating cancer
AU2020315401B2 (en) 2019-07-16 2025-05-22 The Regents Of The University Of Michigan Imidazopyrimidines as EED inhibitors and the use thereof
WO2021032004A1 (zh) 2019-08-22 2021-02-25 上海青煜医药科技有限公司 氮杂芳基化合物及其应用
CA3150284A1 (en) * 2019-09-26 2021-04-01 Novartis Ag Aza-quinoline compounds and uses thereof
AU2020374041B2 (en) * 2019-11-01 2024-02-08 Jing Medicine Technology (Shanghai) Ltd. EED inhibitor, and preparation method therefor and use thereof
CN113004233B (zh) * 2019-12-18 2022-12-20 南京优氟医药科技有限公司 一种用于制备prc2抑制剂的化合物、其制备方法和用途
CN111333655B (zh) * 2020-04-13 2021-07-13 武汉工程大学 一种三唑并嘧啶类化合物及其制备方法和应用
EP4149932B1 (en) * 2020-05-11 2025-08-06 Ascentage Pharma (Suzhou) Co., Ltd. Preparation method of (5-fluoro-2, 3-dihydrobenzofuran-4-yl) methanamine or its salt, and intermediates thereof
CN115916209A (zh) * 2020-05-28 2023-04-04 诺华股份有限公司 用于治疗PRC2介导的疾病或障碍的N-((5-氟-2,3-二氢苯并呋喃-4-基)甲基)-8-(2-甲基吡啶-3-基)-[1,2,4]三唑并[4,3-c]嘧啶-5-胺或其药学上可接受的盐的给药方案
CN114907385A (zh) 2021-02-10 2022-08-16 上海青煜医药科技有限公司 氮杂芳基化合物、其制备方法及应用
CN115703799B (zh) * 2021-08-11 2024-11-08 上海青煜医药科技有限公司 氮杂芳基化合物、其制备方法及应用
CN117384153A (zh) * 2022-07-12 2024-01-12 上海赛岚生物科技有限公司 一类甲基转移酶抑制剂及其用途
WO2024215699A1 (en) * 2023-04-11 2024-10-17 Oric Pharmaceuticals, Inc. Treatment of t-cell lymphoma

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
IL143236A0 (en) 1998-12-16 2002-04-21 Warner Lambert Co Treatment of arthritis with mek inhibitors
NL1014106C2 (nl) 2000-01-18 2001-07-20 Univ Amsterdam Werkwijze voor het detecteren van een pathologische afwijking bij een cel, een antistof en een assay kit.
WO2002006213A2 (en) 2000-07-19 2002-01-24 Warner-Lambert Company Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
SE519662C2 (sv) 2001-07-04 2003-03-25 Asept Int Ab Ventilanordning vid utportioneringsanordningar
WO2003034997A2 (en) * 2001-10-24 2003-05-01 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
US7799827B2 (en) 2002-03-08 2010-09-21 Eisai Co., Ltd. Macrocyclic compounds useful as pharmaceuticals
TWI343377B (en) 2002-03-13 2011-06-11 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
GB0228900D0 (en) 2002-12-11 2003-01-15 Ml Lab Plc Cancer Immunotherapy
JP2004238296A (ja) 2003-02-04 2004-08-26 Kissei Pharmaceut Co Ltd 新規なトリアゾロピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CA2528669A1 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20060246505A1 (en) 2003-09-02 2006-11-02 Reinhard Walther Modulation of the synthesis of insulin
DE602005017781D1 (de) 2004-06-01 2009-12-31 Univ North Carolina Rekonstituierter histon-methyltransferase-komplex und verfahren zur identifizierung von modulatoren dafür
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
WO2007014011A2 (en) 2005-07-21 2007-02-01 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
JO2660B1 (ar) 2006-01-20 2012-06-17 نوفارتيس ايه جي مثبطات الكاينيز Pi-3 وطرق استخدامها
US7890267B2 (en) 2006-03-31 2011-02-15 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
CA2673784A1 (en) 2006-12-27 2008-07-10 Usc Stevens-University Of Southern California Dna methylation markers based on epigenetic stem cell signatures in cancer
WO2009017670A2 (en) 2007-07-26 2009-02-05 University Of Massachusetts Ras-mediated epigenetic silencing effectors and uses thereof
WO2009026720A1 (en) 2007-08-29 2009-03-05 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
AU2008298948B2 (en) 2007-09-12 2014-09-04 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
EP2214675B1 (en) 2007-10-25 2013-11-20 Genentech, Inc. Process for making thienopyrimidine compounds
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
GB0822248D0 (en) 2008-12-05 2009-01-14 Medical Res Council Crystal meths
WO2010111712A2 (en) 2009-03-27 2010-09-30 Cold Spring Harbor Laboratory Identification of rnai targets and use of rnai for rational therapy of chemotherapy-resistant leukemia and other cancers
CN102020643A (zh) * 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
US8536179B2 (en) * 2010-05-07 2013-09-17 Glaxosmithkline Llc Indoles
AU2011298987B2 (en) 2010-09-10 2017-09-28 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
WO2012151277A1 (en) 2011-05-02 2012-11-08 Applied Informatic Solutions, Inc. Kits and methods for selecting a treatment for ovarian cancer
US20140213475A1 (en) 2011-07-14 2014-07-31 University Of Massachusetts Methods of diagnosing cancer using epigenetic biomarkers
BR112014007603A2 (pt) 2011-09-30 2017-06-13 Glaxosmithkline Llc métodos de tratamento do câncer
HUE042271T2 (hu) 2012-03-12 2019-06-28 Epizyme Inc Emberi EZH2 inhibitorai és azok alkalmazási eljárásai
CN105189506A (zh) 2012-11-19 2015-12-23 诺华股份有限公司 用于治疗寄生虫疾病的化合物和组合物
EP2934531A4 (en) 2012-12-19 2016-06-15 Glaxosmithkline Llc COMBINATION
JP2016509014A (ja) 2013-02-08 2016-03-24 ステムセントリックス， インコーポレイテッド 新規の多特異的構成物
ME02730B (me) 2013-02-11 2017-10-20 Constellation Pharmaceuticals Inc Modulatori enzima koji modifikuju metil, njihove kompozicije i upotreba
KR20150127216A (ko) 2013-03-14 2015-11-16 제넨테크, 인크. 암의 치료 및 암 약물 내성의 예방 방법
WO2014151142A1 (en) 2013-03-15 2014-09-25 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9776996B2 (en) 2013-03-15 2017-10-03 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
CA2939219C (en) 2014-02-11 2023-02-28 Mitokinin Llc Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
RU2731051C2 (ru) 2014-11-14 2020-08-28 Басф Се Бензилпропаргиловые простые эфиры в качестве ингибиторов нитрификации
NO3033944T3 (ar) 2014-12-16 2018-07-14
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
MA41272A (fr) 2014-12-23 2017-10-31 Adama Makhteshim Ltd 5-fluoro-4-imino-3-(alkyle/alkyle substitué)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1h)-one en tant que traitement des semences
CN107108637B (zh) * 2014-12-23 2019-10-29 诺华股份有限公司 三唑并嘧啶化合物及其用途

Also Published As

Publication number Publication date
ES2722048T3 (es) 2019-08-07
LT3237418T (lt) 2019-05-10
EP3237418B1 (en) 2019-01-30
US11931363B2 (en) 2024-03-19
KR20170095882A (ko) 2017-08-23
PT3237418T (pt) 2019-05-23
IL252135A0 (en) 2017-07-31
US20200323859A1 (en) 2020-10-15
WO2016103155A1 (en) 2016-06-30
BR112017010354A2 (pt) 2017-12-26
EA032416B1 (ru) 2019-05-31
ECSP17047153A (es) 2019-02-28
AU2015370524A1 (en) 2017-06-01
GT201700146A (es) 2019-06-12
HUE043060T2 (hu) 2019-07-29
BR112017010354B1 (pt) 2022-09-20
EP3237418A1 (en) 2017-11-01
TWI694076B (zh) 2020-05-21
JP2018500342A (ja) 2018-01-11
KR102534028B1 (ko) 2023-05-19
TN2017000204A1 (en) 2018-10-19
US20170348312A1 (en) 2017-12-07
SG11201703880VA (en) 2017-07-28
CA2969090A1 (en) 2016-06-30
UY36462A (es) 2016-07-29
SI3237418T1 (sl) 2019-06-28
PH12017501016A1 (en) 2017-12-11
ME03385B (me) 2020-01-20
US20190142837A1 (en) 2019-05-16
TW201629065A (zh) 2016-08-16
CL2017001572A1 (es) 2018-01-12
CO2017005992A2 (es) 2017-10-20
US20230033320A1 (en) 2023-02-02
JP6736559B2 (ja) 2020-08-05
HRP20190805T1 (hr) 2019-06-28
AU2015370524B2 (en) 2018-11-01
PL3237418T3 (pl) 2019-07-31
BR112017010354B8 (pt) 2022-10-18
MX375970B (es) 2025-03-06
CR20170285A (es) 2017-08-21
DOP2017000149A (es) 2017-07-15
US9580437B2 (en) 2017-02-28
US20160176882A1 (en) 2016-06-23
CA2969090C (en) 2023-05-02
NZ731664A (en) 2024-02-23
CN107108637B (zh) 2019-10-29
CY1121901T1 (el) 2020-10-14
IL252135B (en) 2020-06-30
SV2017005472A (es) 2018-06-12
DK3237418T3 (da) 2019-05-13
CN107108637A (zh) 2017-08-29
RS58679B1 (sr) 2019-06-28
MY186837A (en) 2021-08-25
EA201791420A1 (ru) 2017-10-31
PE20171307A1 (es) 2017-09-05
US10220036B2 (en) 2019-03-05
UA120945C2 (uk) 2020-03-10
MX2017008529A (es) 2017-10-25
PH12017501016B1 (en) 2017-12-11
US11207325B2 (en) 2021-12-28

Similar Documents

Publication Publication Date Title
PH12017501016B1 (en) Triazolopyrimidine compounds and uses thereof
JOP20200192A1 (ar) أجسام مضادة لـ tigit
EA030199B9 (ru) Терапевтически активные соединения и способы их применения
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201501142A1 (ru) Гетероциклические соединения в качестве средств для борьбы с вредителями
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
EA201692219A1 (ru) Способы получения противовирусных соединений
MX391812B (es) Agonista fxr derivado de esteroides.
UA118259C2 (uk) Гетероциклічні аміди як інгібітори кінази
EA201990044A1 (ru) Гетероциклические соединения в качестве антибактериальных средств
EA201890058A1 (ru) Производное глюкагона и композиция, содержащая длительно действующий конъюгат этого производного
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201690478A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТРИАЗОЛ[4,5-d]ПИРИМИДИНА
JO3579B1 (ar) مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
EA201892246A1 (ru) Производные аминотиазола, полученные в качестве противовирусных средств
MA38404A1 (fr) Nouveaux dérivés de pyridine
MY194307A (en) Pyridone derivative having tetrahydropyranylmethyl group
PH12017500095A1 (en) Imidazopyridazine compounds
EA201890632A1 (ru) Хиральные фосфорамидимидаты и их производные
EA201992832A1 (ru) Подкожное введение adamts13
EA201692550A1 (ru) Соединения, содержащие систему 1,1&#39;,2,5&#39;-тетрагидроспиро[индол-3,2&#39;-пиррол]-2,5&#39;-диона в качестве ингибиторов белок-белкового взаимодействия p53-mdm2